Compare · EOLS vs LLY
EOLS vs LLY
Side-by-side comparison of Evolus Inc. (EOLS) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EOLS and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 1959.0x EOLS ($592.8M).
- LLY has been more active in the news (17 items in the past 4 weeks vs 5 for EOLS).
- LLY has more recent analyst coverage (25 ratings vs 7 for EOLS).
- Company
- Evolus Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $592.8M
- $1.16T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 5
- 17
- Recent ratings
- 7
- 25
Evolus Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest EOLS
- SEC Form 10-Q filed by Evolus Inc.
- Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
- Evolus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
- Evolus to Report Second Quarter Financial Results on August 5, 2026
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- Evolus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market